Abstract
Already the 68th Annual AAN (American Academy of Neurology) meeting took place April 15-21, 2016. This year a beautiful canadian city Vancouver was chosen for this occasion and the actual meeting took place in one of the biggest convention centres in North America.
The schedule was very interesting and filled with exciting news. This article focuses on the news regarding multiple sclerosis, such as examining the effect of clemastine to remyelinization in patients with optic neuritis or the effect of minocycline to postponing the transformation from clinically isolated syndrome (CIS) to definitive multiple sclerosis (MS).
Results of couple studies were published during the meeting, for example ASCEND study focusing on the effect of natalizumab in treatment of secondary progressive MS or OPERA I and II study dealing with the effect of treatment with ocrelizumab in patients with relapse-remitting form of MS. I also found very interesting the message of professor Schwab regarding the use of L-selectin to stratify the risk of developing progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab.
Another worth mentioning lecture belonged to Mar Tintóre, who spoke about dynamic model predicting the prognosis of patients with CIS.